-+ 0.00%
-+ 0.00%
-+ 0.00%

Takeda Pharmaceutical Co Lowers FY2026 Adj EPS Guidance from $3.01 to $2.96 vs $1.57 Est; Lowers FY2026 Sales Guidance from $29.585B to $29.116B vs $28.950B Est

Benzinga·07/30/2026 07:44:47
Listen to the news
Takeda Pharmaceutical Co (NYSE:TAK) lowers FY2026 Adj EPS guidance from $3.01 to $2.96 vs $1.57 analyst estimate. Lowers FY2026 sales outlook from $29.585 billion to $29.116 billion vs $28.950 billion estimate.